Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | J.H. Oortweg 21 LEIDEN 2333 CH |
Tel: | N/A |
Website: | https://pharvaris.com |
IR: | See website |
Key People | ||
Berndt Modig Chief Executive Officer, Co-Founder, Executive Director | Jochen Knolle Co-Founder, Chief Operating Officer, Chief Scientific Officer | Hans Schikan Co-Founder, Non-Executive Director |
Anne Lesage Co-Founder, Chief Early Development Officer | David W. Nassif Chief Financial Officer | Anna Nijdam Head of Finance, Principal Accounting Officer |
Morgan Conn Chief Business Officer | Peng Lu Chief Medical Officer | Wim Souverijns Chief Community Engagement and Commercial Officer |
Business Overview |
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE). |
Financial Overview |
For the nine months ended 30 September 2024, Pharvaris NV revenues was not reported. Net loss increased 46% to EUR99.5M. Higher net loss reflects Research & Development Expense - Bal increase of 45% to EUR48.4M (expense), Selling, General & Administrative Expens increase of 63% to EUR20M (expense), Personnel expenses increase of 40% to EUR19M (expense). |